<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7091927/results/search/disease/results.xml">
  <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  <result pre="Organization (WHO) declaration of COVID-19 as a global pandemic. Abstract" exact="Viral" post="infections are a major global health threat. Over the"/>
  <result pre="(WHO) declaration of COVID-19 as a global pandemic. Abstract Viral" exact="infections" post="are a major global health threat. Over the last"/>
  <result pre="of development of antiviral drugs that target influenza virus and" exact="hepatitis" post="B virus, and the future prospects for antivirals from"/>
  <result pre="antivirals from natural products are described and discussed. Subject terms" exact="Viral infection" post="Drug development Introduction Viral infectious diseases cause significant morbidity"/>
  <result pre="from natural products are described and discussed. Subject terms Viral" exact="infection" post="Drug development Introduction Viral infectious diseases cause significant morbidity"/>
  <result pre="described and discussed. Subject terms Viral infection Drug development Introduction" exact="Viral" post="infectious diseases cause significant morbidity and mortality in humans."/>
  <result pre="and discussed. Subject terms Viral infection Drug development Introduction Viral" exact="infectious diseases" post="cause significant morbidity and mortality in humans. Lower respiratory"/>
  <result pre="infectious diseases cause significant morbidity and mortality in humans. Lower" exact="respiratory" post="infections are the deadliest communicable disease, causing 3.2 million"/>
  <result pre="diseases cause significant morbidity and mortality in humans. Lower respiratory" exact="infections" post="are the deadliest communicable disease, causing 3.2 million deaths"/>
  <result pre="and mortality in humans. Lower respiratory infections are the deadliest" exact="communicable disease," post="causing 3.2 million deaths globally in 2015. Moreover, in"/>
  <result pre="causing 3.2 million deaths globally in 2015. Moreover, in 2015" exact="acquired" post="immunodeficiency syndrome (AIDS) caused by human immunodeficiency virus (HIV)"/>
  <result pre="3.2 million deaths globally in 2015. Moreover, in 2015 acquired" exact="immunodeficiency" post="syndrome (AIDS) caused by human immunodeficiency virus (HIV) infections"/>
  <result pre="million deaths globally in 2015. Moreover, in 2015 acquired immunodeficiency" exact="syndrome" post="(AIDS) caused by human immunodeficiency virus (HIV) infections killed"/>
  <result pre="Moreover, in 2015 acquired immunodeficiency syndrome (AIDS) caused by human" exact="immunodeficiency" post="virus (HIV) infections killed 1.1 million people and 36.7"/>
  <result pre="acquired immunodeficiency syndrome (AIDS) caused by human immunodeficiency virus (HIV)" exact="infections" post="killed 1.1 million people and 36.7 million people were"/>
  <result pre="36.7 million people were infected with HIV globally. To combat" exact="viral" post="diseases, both vaccines and antiviral drugs have been employed."/>
  <result pre="drugs have been employed. As a result of global efforts," exact="smallpox" post="caused by variola virus infections was eradicated in 1979"/>
  <result pre="employed. As a result of global efforts, smallpox caused by" exact="variola" post="virus infections was eradicated in 1979 because of smallpox"/>
  <result pre="a result of global efforts, smallpox caused by variola virus" exact="infections" post="was eradicated in 1979 because of smallpox vaccination (by"/>
  <result pre="by variola virus infections was eradicated in 1979 because of" exact="smallpox" post="vaccination (by vaccinia virus). However, the development of effective"/>
  <result pre="infections was eradicated in 1979 because of smallpox vaccination (by" exact="vaccinia" post="virus). However, the development of effective vaccines is difficult"/>
  <result pre="development of antiviral drugs and vaccines is required to combat" exact="viral" post="diseases. Approximately 90 drugs have been approved to treat"/>
  <result pre="diseases. Approximately 90 drugs have been approved to treat human" exact="infectious diseases" post="caused by the following nine viruses: HIV, human cytomegalovirus,"/>
  <result pre="diseases caused by the following nine viruses: HIV, human cytomegalovirus," exact="hepatitis" post="B virus (HBV), hepatitis C virus (HCV), herpes simplex"/>
  <result pre="following nine viruses: HIV, human cytomegalovirus, hepatitis B virus (HBV)," exact="hepatitis" post="C virus (HCV), herpes simplex virus, influenza virus, respiratory"/>
  <result pre="human cytomegalovirus, hepatitis B virus (HBV), hepatitis C virus (HCV)," exact="herpes" post="simplex virus, influenza virus, respiratory syncytial virus, varicella zoster"/>
  <result pre="(HBV), hepatitis C virus (HCV), herpes simplex virus, influenza virus," exact="respiratory" post="syncytial virus, varicella zoster virus and human papillomavirus. In"/>
  <result pre="virus (HCV), herpes simplex virus, influenza virus, respiratory syncytial virus," exact="varicella" post="zoster virus and human papillomavirus. In addition, many antiviral"/>
  <result pre="(HCV), herpes simplex virus, influenza virus, respiratory syncytial virus, varicella" exact="zoster" post="virus and human papillomavirus. In addition, many antiviral drugs"/>
  <result pre="being evaluated in clinical trials. One of the threats of" exact="viral" post="infections is emerging and re-emerging viruses, such as Ebola"/>
  <result pre="evaluated in clinical trials. One of the threats of viral" exact="infections" post="is emerging and re-emerging viruses, such as Ebola virus,"/>
  <result pre="is emerging and re-emerging viruses, such as Ebola virus, severe" exact="acute" post="respiratory syndrome coronavirus, Middle East respiratory syndrome coronavirus and"/>
  <result pre="emerging and re-emerging viruses, such as Ebola virus, severe acute" exact="respiratory" post="syndrome coronavirus, Middle East respiratory syndrome coronavirus and Zika"/>
  <result pre="and re-emerging viruses, such as Ebola virus, severe acute respiratory" exact="syndrome" post="coronavirus, Middle East respiratory syndrome coronavirus and Zika virus."/>
  <result pre="as Ebola virus, severe acute respiratory syndrome coronavirus, Middle East" exact="respiratory" post="syndrome coronavirus and Zika virus. Effective antiviral drugs or"/>
  <result pre="Ebola virus, severe acute respiratory syndrome coronavirus, Middle East respiratory" exact="syndrome" post="coronavirus and Zika virus. Effective antiviral drugs or vaccines"/>
  <result pre="can emerge because of the high mutation rate of the" exact="viral" post="genome exhibited by many viruses, particularly RNA viruses, also"/>
  <result pre="Natural products exhibit great structural diversity and complexity. Thus, both" exact="viral" post="and host proteins involved in viral propagation can be"/>
  <result pre="and complexity. Thus, both viral and host proteins involved in" exact="viral" post="propagation can be targeted to develop antiviral drugs from"/>
  <result pre="Table 2. Table 1 Antiviral compounds isolated in IMC Compound" exact="Viral" post="infections Reference Formycins Influenza virus, poliovirus, vaccinia virus, VSV"/>
  <result pre="2. Table 1 Antiviral compounds isolated in IMC Compound Viral" exact="infections" post="Reference Formycins Influenza virus, poliovirus, vaccinia virus, VSV 3,"/>
  <result pre="in IMC Compound Viral infections Reference Formycins Influenza virus, poliovirus," exact="vaccinia" post="virus, VSV 3, 4 Coformycin HIV 5 Oxanosine HIV"/>
  <result pre="(HIV)d 27, 28 Siastatin B (Influenza virus)e 30 Abbreviations: HBV," exact="hepatitis" post="B virus; HCV, hepatitis C virus; HIV, human immunodeficiency"/>
  <result pre="B (Influenza virus)e 30 Abbreviations: HBV, hepatitis B virus; HCV," exact="hepatitis" post="C virus; HIV, human immunodeficiency virus; HSV, herpes simplex"/>
  <result pre="HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human" exact="immunodeficiency" post="virus; HSV, herpes simplex virus; IMC, Institute of Microbial"/>
  <result pre="virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HSV," exact="herpes" post="simplex virus; IMC, Institute of Microbial Chemistry; VSV, vesicular"/>
  <result pre="herpes simplex virus; IMC, Institute of Microbial Chemistry; VSV, vesicular" exact="stomatitis" post="virus. aInhibition of HIV reverse transcriptase. bInhibition of unknown"/>
  <result pre="Natural compounds with antiviral activities focused in this review Compound" exact="Viral" post="infections Reference Spongouridine Spongothymidine (HSV)a 1, 2 Statins HBV,"/>
  <result pre="compounds with antiviral activities focused in this review Compound Viral" exact="infections" post="Reference Spongouridine Spongothymidine (HSV)a 1, 2 Statins HBV, HIV,"/>
  <result pre="112, 113, 114, 115, 116 Abbreviations: DENV, dengue virus; HBV," exact="hepatitis" post="B virus; HCMV, human cytomegalovirus; HCV, hepatitis C virus;"/>
  <result pre="dengue virus; HBV, hepatitis B virus; HCMV, human cytomegalovirus; HCV," exact="hepatitis" post="C virus; HIV, human immunodeficiency virus; HSV, herpes simplex"/>
  <result pre="virus; HCMV, human cytomegalovirus; HCV, hepatitis C virus; HIV, human" exact="immunodeficiency" post="virus; HSV, herpes simplex virus; HPV, human papillomavirus. aContributed"/>
  <result pre="cytomegalovirus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HSV," exact="herpes" post="simplex virus; HPV, human papillomavirus. aContributed to the synthesis"/>
  <result pre="approved antiviral drugs that exert therapeutic effects through incorporation into" exact="viral" post="DNA and RNA to inhibit virus replication. To date,"/>
  <result pre="of vidarabine (arabinosyladenine), which is used for the treatment of" exact="herpes" post="simplex virus infections. Professor Umezawa and colleagues identified nucleoside"/>
  <result pre="This drug had initially been used for chemotherapeutic intervention against" exact="HIV infection," post="but unmet medical needs of increased efficacy, reduced adverse"/>
  <result pre="viruses: phleomycin (anti-poliovirus activity),14 fusaric acid (broad-spectrum antiviral activity against" exact="herpes" post="simplex virus, varicella-zoster virus, HBV, HCV and sindbis virus),15"/>
  <result pre="as a consequence of interactions with cellular DNA.19 Currently, microbial" exact="secondary" post="metabolites are well established to contain many compounds with"/>
  <result pre="anti-HIV drugs in highly active antiretroviral therapy. HIV proteinase processes" exact="viral" post="polyproteins to generate mature proteins and is essential for"/>
  <result pre="for antiviral drugs. Influenza virus Influenza virus Seasonal influenza is" exact="acute" post="respiratory infections caused by influenza viruses. There are three"/>
  <result pre="antiviral drugs. Influenza virus Influenza virus Seasonal influenza is acute" exact="respiratory" post="infections caused by influenza viruses. There are three types"/>
  <result pre="drugs. Influenza virus Influenza virus Seasonal influenza is acute respiratory" exact="infections" post="caused by influenza viruses. There are three types of"/>
  <result pre="and development of new antiviral drugs and vaccines against influenza" exact="infections" post="are required. A total of eight drugs (matrix 2"/>
  <result pre="antiviral drugs and vaccines against influenza infections are required. A" exact="total" post="of eight drugs (matrix 2 (M2) inhibitors (amantadine and"/>
  <result pre="rimantadine), NA inhibitors (zanamivir, oseltamivir, peramivir and laninamivir octanoate) and" exact="viral" post="RNA-dependent RNA polymerase inhibitors (ribavirin and favipiravir) have been"/>
  <result pre="Acidification in the virion interior is necessary to allow the" exact="viral" post="genome to diffuse away from the endosomal membrane. Amantadine"/>
  <result pre="virion interior is necessary to allow the viral genome to" exact="diffuse" post="away from the endosomal membrane. Amantadine inhibits proton translocation"/>
  <result pre="the M2 protein tetramer, thereby inducing the release of the" exact="viral" post="genome into the cytoplasm35 (Figure 1). However, amantadine and"/>
  <result pre="of amantadine, are not currently used to treat influenza virus" exact="infections" post="because drug-resistant viruses can emerge rapidly (both the A/H1N1pdm"/>
  <result pre="seasonal epidemic strains have the amantadine-resistance S31N mutation) and the" exact="central nervous system" post="side effects are particularly common in patients treated with"/>
  <result pre="virus is incorporated into the cell via endocytotic pathway and" exact="viral" post="ribonucleoprotein complex (vRNP) which consists of viral genome RNA,"/>
  <result pre="endocytotic pathway and viral ribonucleoprotein complex (vRNP) which consists of" exact="viral" post="genome RNA, viral polymerases and nucleoprotein is released into"/>
  <result pre="viral ribonucleoprotein complex (vRNP) which consists of viral genome RNA," exact="viral" post="polymerases and nucleoprotein is released into the cytoplasm. vRNP"/>
  <result pre="Budding of progeny virion is occurred under plasma membrane with" exact="viral" post="membrane proteins (HA, NA and M2). Amantadine and rimantadine"/>
  <result pre="of vRNP into cytoplasm. VX-787 and S-033188 inhibit transcription of" exact="viral" post="mRNA by binding to viral polymerase complex. Favipiravir and"/>
  <result pre="and S-033188 inhibit transcription of viral mRNA by binding to" exact="viral" post="polymerase complex. Favipiravir and ribavirin inhibit viral RNA synthesis."/>
  <result pre="by binding to viral polymerase complex. Favipiravir and ribavirin inhibit" exact="viral" post="RNA synthesis. Zanamivir, oseltamivir, peramivir and laninamivir octanoate all"/>
  <result pre="not inhibit that of influenza virus (A/Aichi/2/68 strain) NA and" exact="Newcastle disease" post="virus (Sato strain) HN.29 A siastatin B epimeric analog,"/>
  <result pre="inhibit that of influenza virus (A/Aichi/2/68 strain) NA and Newcastle" exact="disease" post="virus (Sato strain) HN.29 A siastatin B epimeric analog,"/>
  <result pre="treatment for influenza A and B viruses. Virus polymerase inhibitors" exact="Viral" post="polymerase complex is a promising target for the development"/>
  <result pre="and replication are critical steps for virus propagation. Moreover, the" exact="viral" post="polymerase complex acts by a specific molecular mechanism for"/>
  <result pre="viral polymerase complex acts by a specific molecular mechanism for" exact="viral" post="transcription and replication. The viral polymerase complex is a"/>
  <result pre="a specific molecular mechanism for viral transcription and replication. The" exact="viral" post="polymerase complex is a heterotrimer composed of three subunits:"/>
  <result pre="three subunits: PA, PB1 and PB2. At the initiation of" exact="viral" post="mRNA transcription, influenza viral polymerase cannot synthesize the 5′-cap"/>
  <result pre="and PB2. At the initiation of viral mRNA transcription, influenza" exact="viral" post="polymerase cannot synthesize the 5′-cap structure of mRNA that"/>
  <result pre="PA subunit. Using this capped fragment as a primer, the" exact="viral" post="polymerase complex synthesizes viral mRNA. These processes have been"/>
  <result pre="capped fragment as a primer, the viral polymerase complex synthesizes" exact="viral" post="mRNA. These processes have been targeted in the development"/>
  <result pre="infections. Two approved drugs, ribavirin and T-705 (favipiravir), inhibit influenza" exact="viral" post="RNA synthesis (Figure 1). Ribavirin is a synthetic nucleoside"/>
  <result pre="and GTP.49 Ribavirin has not been used to treat influenza" exact="virus infection," post="but has been used for HCV infections along with"/>
  <result pre="treat influenza virus infection, but has been used for HCV" exact="infections" post="along with pegylated interferon. T-705 is a pyrazine derivative"/>
  <result pre="specific inhibitor of influenza virus RNA synthesis. T705-4-ribofuranosyl-5′-triphosphate directly inhibits" exact="viral" post="RNA synthesis and is incorporated into synthesized RNA in"/>
  <result pre="infectivity. T-705 has been approved for use against pandemic influenza" exact="infections" post="in Japan. Natural products for anti-influenza virus infections All"/>
  <result pre="pandemic influenza infections in Japan. Natural products for anti-influenza virus" exact="infections" post="All of the approved and clinical trial drugs mentioned"/>
  <result pre="inhibiting membrane fusion between virus and host cells.56, 57, 58" exact="Hepatitis" post="B virus According to the World Health Organization estimates"/>
  <result pre="estimates in 2016, the annual number of deaths resulting from" exact="viral hepatitis" post="is ~1.4 million, which is comparable to that of"/>
  <result pre="in 2016, the annual number of deaths resulting from viral" exact="hepatitis" post="is ~1.4 million, which is comparable to that of"/>
  <result pre="with HBV worldwide and have an elevated risk of developing" exact="liver cirrhosis" post="and hepatocellular carcinoma.60 Current antiviral drugs approved by the"/>
  <result pre="HBV worldwide and have an elevated risk of developing liver" exact="cirrhosis" post="and hepatocellular carcinoma.60 Current antiviral drugs approved by the"/>
  <result pre="tenofovir), which are useful for therapeutic treatment to interrupt the" exact="disease" post="progression. However, these drug classes have certain limitations; for"/>
  <result pre="However, these drug classes have certain limitations; for immunomodulators, a" exact="partial" post="efficacy and side effects exist, and for nucleos(t)ide analogs,"/>
  <result pre="products with anti-HBV activities, as compared with phytochemicals,61, 62 are" exact="limited" post="to date, microbial metabolites may represent a fundamental source"/>
  <result pre="into covalently closed circular DNA (cccDNA). The cccDNA is quite" exact="stable" post="in the form of a minichromosome and serves as"/>
  <result pre="and serves as a template for the transcription of all" exact="viral" post="mRNAs. Among these mRNAs, the 3.5 kb pregenomic RNA is"/>
  <result pre="to supply the cccDNA pool. Figure 2 Life cycle of" exact="hepatitis" post="B virus (HBV). HBV enters hepatocytes following binding to"/>
  <result pre="capsid. In the nucleus, rcDNA is converted into cccDNA by" exact="viral" post="and cellular enzymes. The cccDNA is quite stable in"/>
  <result pre="cccDNA by viral and cellular enzymes. The cccDNA is quite" exact="stable" post="in the form of a minichromosome that is responsible"/>
  <result pre="form of a minichromosome that is responsible for persistent HBV" exact="infection" post="and transcribed by host RNA polymerase II to generate"/>
  <result pre="mRNA, and 0.7 kb HBx mRNA. pgRNA is translated into the" exact="viral" post="polymerase and core proteins, which is then encapsidated together"/>
  <result pre="huge amounts of subviral HBsAg particles are assembled in the" exact="absence of" post="nucleocapsid and released. The other 3.5 kb mRNA is translated"/>
  <result pre="HBeAg. HBx has a multifunctional role in activation of various" exact="viral" post="and cellular promoters and enhancers. A Full color version"/>
  <result pre="development, it is important to select potential therapeutic targets for" exact="chronic" post="HBV infection from the virus life cycle. Although various"/>
  <result pre="is important to select potential therapeutic targets for chronic HBV" exact="infection" post="from the virus life cycle. Although various anti-HBV drugs,"/>
  <result pre="drug development Approved nucleos(t)ide analogs competitively inhibit DNA elongation of" exact="viral" post="polymerase after the conversion to triphosphate form by cellular"/>
  <result pre="Although nucleos(t)ide analog inhibitors can be highly effective in preventing" exact="liver disease" post="progression, these drugs are not curative and require long-term"/>
  <result pre="nucleos(t)ide analog inhibitors can be highly effective in preventing liver" exact="disease" post="progression, these drugs are not curative and require long-term"/>
  <result pre="The ideal goal of anti-HBV treatments is the loss of" exact="viral" post="surface antigens, HBsAg, which is correlated with dramatic reduction"/>
  <result pre="HBsAg, which is correlated with dramatic reduction of incidence of" exact="hepatocellular carcinoma." post="However, current nucleos(t)ide inhibitors are ineffective in this regard,"/>
  <result pre="treatment outcomes, novel anti-HBV agents that target other steps of" exact="viral" post="DNA synthesis, in combination with current HBV drugs, may"/>
  <result pre="The core protein self-assembles to form a nucleocapsid in which" exact="viral" post="DNA synthesis is carried out, and several inhibitors of"/>
  <result pre="inhibitors may facilitate cccDNA decay because the strong inhibition of" exact="viral" post="DNA synthesis is thought to completely block the recycling"/>
  <result pre="H-mediated pregenomic RNA degradation is another essential step for the" exact="viral" post="DNA synthesis and a novel inhibitor of this activity"/>
  <result pre="for the rapid drug screening of natural resources. As HBV" exact="infection" post="is significantly influenced by various of host factors, host"/>
  <result pre="for development as antiviral drugs that disrupt the folding of" exact="viral" post="glycoproteins by inhibiting host glucosidase, which is localized to"/>
  <result pre="folding of viral glycoproteins by inhibiting host glucosidase, which is" exact="localized" post="to the endoplasmic reticulum.85 Deoxynojirimycin is of plant origin,"/>
  <result pre="microbial metabolites. Furthermore, several therapeutic vaccines for the treatment of" exact="chronic" post="HBV infection are in preclinical and clinical trials. This"/>
  <result pre="Furthermore, several therapeutic vaccines for the treatment of chronic HBV" exact="infection" post="are in preclinical and clinical trials. This approach aims"/>
  <result pre="prospects for natural products in antiviral drug development Recently, deadly" exact="disease" post="outbreaks caused by emerging and re-emerging viruses have become"/>
  <result pre="Hantavirus in the United States, Ebola virus in Africa, severe" exact="acute" post="respiratory syndrome and Middle East respiratory syndrome coronaviruses in"/>
  <result pre="in the United States, Ebola virus in Africa, severe acute" exact="respiratory" post="syndrome and Middle East respiratory syndrome coronaviruses in China"/>
  <result pre="the United States, Ebola virus in Africa, severe acute respiratory" exact="syndrome" post="and Middle East respiratory syndrome coronaviruses in China and"/>
  <result pre="virus in Africa, severe acute respiratory syndrome and Middle East" exact="respiratory" post="syndrome coronaviruses in China and Mideast, Zika virus in"/>
  <result pre="in Africa, severe acute respiratory syndrome and Middle East respiratory" exact="syndrome" post="coronaviruses in China and Mideast, Zika virus in Oceania"/>
  <result pre="broad-spectrum RNA virus inhibitor and an antiviral candidate for emerging" exact="infectious diseases," post="such as dengue virus, norovirus, and Hendra and Nipah"/>
  <result pre="be exerted by both the direct and indirect inhibition of" exact="viral" post="polymerase activity. Ribavirin monophosphate inhibits inosine-5′-monophosphate dehydrogenase, which catalyzes"/>
  <result pre="that result from ribavirin treatment could cause a reduction of" exact="viral" post="polymerase activity and the incorporation of alternative nucleotides for"/>
  <result pre="from host cells. Inhibitors against such cellular machinery could inhibit" exact="viral" post="propagation. These host targeted drugs are not yet approved"/>
  <result pre="of CsA involves the inhibition of the correct folding of" exact="viral" post="proteins by cyclophilins. CsA exerts immunosuppressive effects as the"/>
  <result pre="drug and is the subject of a clinical trial.119 Today," exact="viral" post="proteins are the major target of antiviral drugs. Antiviral"/>
  <result pre="drugs against specific target proteins have been successful against important" exact="infectious diseases," post="such as HIV and HCV. With rapidly increasing knowledge"/>
  <result pre="developed that will contribute to the future elimination of specific" exact="infectious diseases." post="Concurrently, we now face the threat of emerging and"/>
  <result pre="Concurrently, we now face the threat of emerging and re-emerging" exact="infectious diseases" post="with no available specific antiviral drug. To prevent a"/>
  <result pre="products will contribute to both the elimination of specific virus" exact="infections" post="and emerging virus infections in the future. Dedication We"/>
  <result pre="both the elimination of specific virus infections and emerging virus" exact="infections" post="in the future. Dedication We dedicate this review to"/>
  <result pre="Antibiot. (Tokyo)198134121912217328061 9HoshinoHSekiJTakeuchiTNew antifungal antibiotics, benanomicins A and B inhibit" exact="infection" post="of T-cell with human immunodeficiency virus (HIV) and syncytium"/>
  <result pre="benanomicins A and B inhibit infection of T-cell with human" exact="immunodeficiency" post="virus (HIV) and syncytium formation by HIVJ. Antibiot. (Tokyo)1989423443462784430"/>
  <result pre="formation by HIVJ. Antibiot. (Tokyo)1989423443462784430 10NakamuraMOhnoTKunimotoSNaganawaHTakeuchiTKijimicin: an inhibitor of human" exact="immunodeficiency" post="virus in acutely and chronically infected cellsJ. Antibiot. (Tokyo)1991445695712061199"/>
  <result pre="chronically infected cellsJ. Antibiot. (Tokyo)1991445695712061199 11KondoSNew bellenamine homologs inhibiting human" exact="immunodeficiency" post="virus type I infectivityJ. Antibiot. (Tokyo)1996491131188609077 12AjitoKInhibition of human"/>
  <result pre="cellsJ. Antibiot. (Tokyo)1991445695712061199 11KondoSNew bellenamine homologs inhibiting human immunodeficiency virus" exact="type I" post="infectivityJ. Antibiot. (Tokyo)1996491131188609077 12AjitoKInhibition of human immunodeficiency virus-associated reverse"/>
  <result pre="immunodeficiency virus type I infectivityJ. Antibiot. (Tokyo)1996491131188609077 12AjitoKInhibition of human" exact="immunodeficiency" post="virus-associated reverse transcriptase by 14-O-acyladriamycinsJ. Antibiot. (Tokyo)1989426116192470719 13AtsumiSInhibition of"/>
  <result pre="virus-associated reverse transcriptase by 14-O-acyladriamycinsJ. Antibiot. (Tokyo)1989426116192470719 13AtsumiSInhibition of human" exact="immunodeficiency" post="virus-associated reverse transcriptase by aminoacridinesDrugs Exp. Clin. Res.1988147197222472939 14KochGDifferential"/>
  <result pre="growth regulation in Archaea, eukaryotic cells, DNA repair, translation and" exact="viral" post="replicationCancer Genomics Proteomics2011810512621518817 16TanakaASenKMoritaJKomanoTPhage inactivation by aclacinomycin A and"/>
  <result pre="Virol.199367468846958392608 25BelovGABidirectional increase in permeability of nuclear envelope upon poliovirus" exact="infection" post="and accompanying alterations of nuclear poresJ. Virol.200478101661017715331749 26UmezawaHAoyagiTMorishimaHMatsuzakiMHamadaMPepstatin, a"/>
  <result pre="45te VelthuisAJWFodorEInfluenza virus RNA polymerase: insights into the mechanisms of" exact="viral" post="RNA synthesisNat. Rev. Microbiol.20161447949327396566 46ByrnRAPreclinical activity of VX-787, a"/>
  <result pre="and biological activitiesJ. Antibiot. (Tokyo)20025515516412002997 58NakataniMNakamuraMSuzukiAInoueMKatohTA new strategy toward the" exact="total" post="synthesis of stachyflin, a potent anti-influenza a virus agent:"/>
  <result pre="structureOrg. Lett.200244483448612465918 59World Health Organization Global Health Sector Strategy on" exact="Viral" post="Hepatitis 2016-2021, World Health Organization, Geneva, Switzerland, (2016). 60World"/>
  <result pre="Lett.200244483448612465918 59World Health Organization Global Health Sector Strategy on Viral" exact="Hepatitis" post="2016-2021, World Health Organization, Geneva, Switzerland, (2016). 60World Health"/>
  <result pre="Organization, Geneva, Switzerland, (2016). 60World Health OrganizationMedia centre. Fact sheets." exact="Hepatitis" post="B (2017) http://www.who.int/mediacentre/factsheets/fs204/en/Accessed 27 May 2017. 61ZhangFWangGA review of"/>
  <result pre="63YanHSodium taurocholate cotransporting polypeptide is a functional receptor for human" exact="hepatitis" post="B and D virusElife20121128 64Hepatitis B Foundation. Treatment &amp;amp;"/>
  <result pre="oxetanocin G, a novel nucleoside analog, on DNA synthesis by" exact="hepatitis" post="B virus virionsAntimicrob. Agents Chemother.1994387077127518217 67NagahataTUedaKTsurimotoTChisakaOMatsubaraKAnti-hepatitis B virus activities"/>
  <result pre="oxetanocin AJ. Antibiot. (Tokyo)1989426446462722678 68WangXEmerging antivirals for the treatment of" exact="hepatitis" post="BWorld J. Gastroenterol.201420770724976708 69SummersJSmithPMHorwichALHepadnavirus envelope proteins regulate covalently closed"/>
  <result pre="closed circular DNA amplificationJ. Virol.199064281928242335817 70LevreroMControl of cccDNA function in" exact="hepatitis" post="B virus infectionJ. Hepatol.20095158159219616338 71YangLIsothiafludine, a novel non-nucleoside compound,"/>
  <result pre="B virus infectionJ. Hepatol.20095158159219616338 71YangLIsothiafludine, a novel non-nucleoside compound, inhibits" exact="hepatitis" post="B virus replication through blocking pregenomic RNA encapsidationActa Pharmacol."/>
  <result pre="through blocking pregenomic RNA encapsidationActa Pharmacol. Sin.20143541041824487969 72YangLEffect of a" exact="hepatitis" post="B virus inhibitor, NZ-4, on capsid formationAntiviral Res.2016125253326611395 73HuYChengXCaoFHuangATavisJEβ-Thujaplicinol"/>
  <result pre="B virus inhibitor, NZ-4, on capsid formationAntiviral Res.2016125253326611395 73HuYChengXCaoFHuangATavisJEβ-Thujaplicinol inhibits" exact="hepatitis" post="B virus replication by blocking the viral ribonuclease H"/>
  <result pre="Res.2016125253326611395 73HuYChengXCaoFHuangATavisJEβ-Thujaplicinol inhibits hepatitis B virus replication by blocking the" exact="viral" post="ribonuclease H activityAntiviral Res.20139922122923796982 74LuGHydroxylated tropolones inhibit hepatitis B"/>
  <result pre="blocking the viral ribonuclease H activityAntiviral Res.20139922122923796982 74LuGHydroxylated tropolones inhibit" exact="hepatitis" post="B virus replication by blocking viral ribonuclease H activityAntimicrob."/>
  <result pre="Res.20139922122923796982 74LuGHydroxylated tropolones inhibit hepatitis B virus replication by blocking" exact="viral" post="ribonuclease H activityAntimicrob. Agents Chemother.2015591070107925451058 75KitamuraSIidaTShirahataKKaseHStudies on lipoxygenase inhibitors."/>
  <result pre="by Streptoverticillium hadanonense KY11449J. Antibiot. (Tokyo)1986395895933086266 76SuzukiMEfficient genome replication of" exact="hepatitis" post="B virus using adenovirus vector: a compact pregenomic RNA-expression"/>
  <result pre="adenovirus vector: a compact pregenomic RNA-expression unitSci. Rep.201774185128157182 77GehringABertolettiATavisJEHost factor-targeted" exact="hepatitis" post="B virus therapiesIntervirology20145715816225034483 78EzzikouriSRecent insights into hepatitis B virus-host"/>
  <result pre="Rep.201774185128157182 77GehringABertolettiATavisJEHost factor-targeted hepatitis B virus therapiesIntervirology20145715816225034483 78EzzikouriSRecent insights into" exact="hepatitis" post="B virus-host interactionsJ. Med. Virol.20148692593224604126 79GriponPCannieIUrbanSEfficient inhibition of hepatitis"/>
  <result pre="into hepatitis B virus-host interactionsJ. Med. Virol.20148692593224604126 79GriponPCannieIUrbanSEfficient inhibition of" exact="hepatitis" post="B virus infection by acylated peptides derived from the"/>
  <result pre="B virus-host interactionsJ. Med. Virol.20148692593224604126 79GriponPCannieIUrbanSEfficient inhibition of hepatitis B" exact="virus infection" post="by acylated peptides derived from the large viral surface"/>
  <result pre="virus-host interactionsJ. Med. Virol.20148692593224604126 79GriponPCannieIUrbanSEfficient inhibition of hepatitis B virus" exact="infection" post="by acylated peptides derived from the large viral surface"/>
  <result pre="B virus infection by acylated peptides derived from the large" exact="viral" post="surface proteinJ. Virol.2005791613162215650187 80VolzTThe entry inhibitor Myrcludex-B efficiently blocks"/>
  <result pre="blocks intrahepatic virus spreading in humanized mice previously infected with" exact="hepatitis" post="B virusJ. Hepatol.20135886186723246506 81NkongoloSCyclosporin A inhibits hepatitis B and"/>
  <result pre="previously infected with hepatitis B virusJ. Hepatol.20135886186723246506 81NkongoloSCyclosporin A inhibits" exact="hepatitis" post="B and hepatitis D virus entry by cyclophilin-independent interference"/>
  <result pre="hepatitis B virusJ. Hepatol.20135886186723246506 81NkongoloSCyclosporin A inhibits hepatitis B and" exact="hepatitis" post="D virus entry by cyclophilin-independent interference with the NTCP"/>
  <result pre="the NTCP receptorJ. Hepatol.20146072373124295872 82WatashiKCyclosporin A and its analogs inhibit" exact="hepatitis" post="B virus entry into cultured hepatocytes through targeting a"/>
  <result pre="membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)Hepatology2014591726173724375637 83BlockTMSecretion of human" exact="hepatitis" post="B virus is inhibited by the imino sugar N-butyldeoxynojirimycinProc."/>
  <result pre="the imino sugar N-butyldeoxynojirimycinProc. Natl Acad. Sci. USA199491223522398134380 84BlockTMTreatment of" exact="chronic" post="hepadnavirus infection in a woodchuck animal model with an"/>
  <result pre="sugar N-butyldeoxynojirimycinProc. Natl Acad. Sci. USA199491223522398134380 84BlockTMTreatment of chronic hepadnavirus" exact="infection" post="in a woodchuck animal model with an inhibitor of"/>
  <result pre="a DNA vaccine for HIV-1Clin. Exp. Immunol.199811130359472658 88WrightPJCrameriGEatonBTRNA synthesis during" exact="infection" post="by Hendra virus: an examination by quantitative real-time PCR"/>
  <result pre="agentProc. Natl Acad. Sci. USA197370117411784197928 92OestereichLSuccessful treatment of advanced Ebola" exact="virus infection" post="with T-705 (favipiravir) in a small animal modelAntiviral Res.2014105172124583123"/>
  <result pre="Natl Acad. Sci. USA197370117411784197928 92OestereichLSuccessful treatment of advanced Ebola virus" exact="infection" post="with T-705 (favipiravir) in a small animal modelAntiviral Res.2014105172124583123"/>
  <result pre="Res.2014105172124583123 93SmitherSJPost-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola" exact="virus infection" post="in a mouse modelAntiviral Res201410415315524462697 94WarrenTKProtection against filovirus diseases"/>
  <result pre="93SmitherSJPost-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus" exact="infection" post="in a mouse modelAntiviral Res201410415315524462697 94WarrenTKProtection against filovirus diseases"/>
  <result pre="of the adenosine analogue BCX4430 against West Nile virus and" exact="tick-borne" post="flavivirusesAntiviral Res.2017142636728336346 97JulanderJGBCX4430, a novel nucleoside analog, effectively treats"/>
  <result pre="tick-borne flavivirusesAntiviral Res.2017142636728336346 97JulanderJGBCX4430, a novel nucleoside analog, effectively treats" exact="yellow fever" post="in a hamster modelAntimicrob. Agents Chemother.2014586607661425155605 98JulanderJGEfficacy of the"/>
  <result pre="on influenza virus infectionMol. Med. Rep.201492221222624676773 104GiguèreJTremblayMJStatin compounds reduce human" exact="immunodeficiency" post="virus type 1 replication by preventing the interaction between"/>
  <result pre="virus infectionMol. Med. Rep.201492221222624676773 104GiguèreJTremblayMJStatin compounds reduce human immunodeficiency virus" exact="type 1" post="replication by preventing the interaction between virion-associated host intercellular"/>
  <result pre="molecule 1 and its natural cell statin compounds reduce human" exact="immunodeficiency" post="virus type 1 replicaJ. Virol.2004781514671082 105BaderTKorbaBSimvastatin potentiates the anti-hepatitis"/>
  <result pre="and its natural cell statin compounds reduce human immunodeficiency virus" exact="type 1" post="replicaJ. Virol.2004781514671082 105BaderTKorbaBSimvastatin potentiates the anti-hepatitis B virus activity"/>
  <result pre="arbomycesJ. Antibiot. (Tokyo)197222109115 108SakamotoHHost sphingolipid biosynthesis as a target for" exact="hepatitis" post="C virus therapyNat. Chem. Biol.2005133333716408072 109TatematsuKTanakaYSugiyamaMSudohMMizokamiMHost sphingolipid biosynthesis is"/>
  <result pre="biosynthesis is a promising therapeutic target for the inhibition of" exact="hepatitis" post="B virus replicationJ. Med. Virol.20118358759321328371 110TafesseFGIntact sphingomyelin biosynthetic pathway"/>
  <result pre="Acad. Sci. USA20131106406641123576732 111Bienkowska-HabaMWilliamsCKimSMGarceaRLSappMCyclophilins facilitate dissociation of the human papillomavirus" exact="type 16" post="capsid protein L1 from the L2/DNA complex following virus"/>
  <result pre="the L2/DNA complex following virus entryJ. Virol.2012869875988722761365 112KarpasALowdellMJacobsonSKHillFInhibition of human" exact="immunodeficiency" post="virus and growth of infected T cells by the"/>
  <result pre="replication and reactivationJ. Gen. Virol.20129372273222238232 116WatashiKHijikataMHosakaMYamajiMShimotohnoKCyclosporin A suppresses replication of" exact="hepatitis" post="C virus genome in cultured hepatocytesHepatology2003381282128814578868 117MatsudaSKoyasuSMechanisms of action"/>
 </snippets>
</snippetsTree>
